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Left sided breast cancer
is associated with aggressive
biology and worse outcomes
than right sided breast cancer
Yara Abdou1*, Medhavi Gupta2, Mariko Asaoka3, Kristopher Attwood4, Opyrchal Mateusz5,
Shipra Gandhi6 & Kazuaki Takabe3,7,8,9,10,11
Breast cancer is more common on the left side than the right side. We aim to evaluate differences in
clinicopathological and genomic characteristics based on laterality. We analyzed survival outcomes
and clinical characteristics of 881,320 patients recorded by the Surveillance, Epidemiology, and
End Results (SEER) program. The Cancer Genome Atlas (TCGA) was used to explore genomic and
clinical features from 1,062 patients. Gene expression data was used to quantitate cytolytic activity
and hallmark gene-sets were used for gene set enrichment analysis. An institutional retrospective
review was conducted on 155 patients treated with neoadjuvant chemotherapy (NACT). Patient
characteristics were summarized by pathological complete response (pCR). Left sided tumors were
found to be more prevalent than right sided tumors. No major clinicopathological differences were
noted by laterality. Left sided breast cancer demonstrated poorer outcomes versus right sided
tumors (HR 1.05, 95% CI 1.01–1.08; p = 0.011). Cell proliferation gene sets, including E2F Targets, G2M
Checkpoint, Mitotic spindle, and MYC Targets, were enriched on the left side compared to the right.
Left sided tumors had lower pCR rates versus right sided tumors (15.4% versus 29.9%, p = 0.036).
Our findings suggest that left sided breast cancer is associated with aggressive biology and worse
outcomes compared to right sided breast cancer.
Published literature on breast cancer laterality is limited, with the first study published approximately 80 years
ago by Fellenberg et al.1 raising awareness to an increased frequency of left sided breast cancer. Since then, it
has been consistently reported that women are slightly more likely to be diagnosed with breast cancer in the left
breast than in the right, with the ratio of left to right side tumors ranging between 1.05 to 1.262–4. Despite the
consistency of this predominance of left sided breast cancer, meaningful underlying characteristic differences
between the two sides have not been well investigated.
The breast is a paired organ and both sides share identical genetic and environmental risk factors that contribute to cancer development. However, studies have shown that paired organs may differ in their tissue structure,
arterial and venous supplies and lymphatic drainage during embryonic d
 evelopment5 leading to biological differences between both sides and a possible association with cancer l aterality6.
Prior studies have tried to explain this left sided predominance through various hypothesis including, larger
size of left b
 reast7, early detection of left tumors in right handed w
 omen8, and preferential right sided breast
feeding9. However, these explanations have not been confirmed by subsequent research or uniformly accepted.
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Various factors on breast cancer laterality have been reported such as; laterality ratio varies with age4,10–12, different quadrants of the breast may have different laterality r atios3,11, and possible correlation between laterality and
genetic inheritance2. Nevertheless, this subject continues to be a complex and poorly understood phenomenon.
Recently our group has been investigating the cancer biology of breast cancer using clinical and gene expression data from The Cancer Genome Atlas (TCGA)13–19. Computational algorithms such as cytolytic activity score
(CYT)17,18,20–23 and gene set enrichment analysis (GSEA)17–19,23 allow us to characterize the biological quality of
the tumor.
Here we hypothesize that left-sided breast cancer is biologically aggressive and has worse outcomes compared
to right-sided breast cancer. We evaluate the clinical and pathological differences between left and right sided
breast cancer using a large patient cohort. We also evaluate differences in cancer biology by computational
biological analyses. Finally, we investigate the clinical relevance of laterality by analyzing a neoadjuvant cohort.

Methods

The surveillance, epidemiology, and end results (SEER) database analyses. SEER database was
interrogated for n = 1,614,013 breast cancer patients with laterality information from 1988 to 2015. Male patients,
patients < 18 years of age, and patients with bilateral disease, DCIS, stage IV, missing stage or survival outcomes
were excluded from analysis. Patient demographic and clinical characteristics were summarized by side (left
versus right) using the appropriate descriptive statistics, with comparisons made using the Mann–Whitney U
or Pearson chi-square tests. Overall Survival (OS) and Cancer Specific Survival (CSS) were summarized by side
(in the overall sample and within each AJCC stage) using standard Kaplan–Meier methods, where estimates of
the median OS and CSS were obtained with 95% confidence intervals (CIs). Comparisons were made using the
log-rank test. Multivariable analyses were conducted using Cox regression models, where the demographic and
clinical characteristics in Table 1 were included as covariates (selected a priori). Hazard ratios (HRs) and corresponding 95% confidence intervals were obtained from model estimates. To evaluate the impact of side within
demographic and clinical subgroups, Cox regression models were fit in a one-at-a-time manner with side, the
sub-group variable, and their two-way interaction as predictors. From the model estimates, hazard ratios are
obtained for side within each sub-group and Wald chi-square tests were used to evaluate the interaction term.
Analyses were conducted in SAS v9.4 (Cary, NC) at a significance level of 0.05. SEER database is a deidentified
public database, therefore no institutional review board (IRB) approval was needed.
Computational biology analyses. Clinical and gene expression data in n = 1,062 breast cancer patients

(552 left sided, 510 right sided) were obtained from The Cancer Genome Atlas (TCGA) as we have previously
described13–19. Lymphovascular Invasion (LVI) status, mitotic rate, nuclear score and tubular score and Nottingham pathological grade score data were collected manually from pathology reports in TIES client 5.8. Fisher’s
exact test was used for group comparisons. Cytolytic activity (CYT) indicates anti-cancer immune response and
was quantified from gene expression data as we have previously described17,18,20–25. Hallmark gene-sets were used
for gene set enrichment analysis (GSEA) as previously described17–19,23,26,27.

Analyses of a neoadjuvant chemotherapy cohort. A retrospective, single-institute review was conducted for a total of n = 155 breast cancer patients treated at Roswell Park Comprehensive Cancer Center, Buffalo NY from 2009 to 2013. Eligible patients were treated with neoadjuvant chemotherapy, followed by either a
lumpectomy or mastectomy. Pathologic complete response (pCR) was defined as an absence of any evidence of
invasive carcinoma in the surgical pathology specimen i.e., ypT0/is N0. Patient characteristics were summarized
by pCR using the appropriate descriptive statistics; with comparisons were made using the Mann–Whitney U
or Fisher’s exact tests. A multivariate logistic regression model was used to evaluate the association between
side and pCR while adjusting for disease grade and hormone receptor status. Odds ratios, with 95% CIs, were
obtained from model estimates. Analyses were conducted in SAS v9.4 (Cary, NC) at a significance level of 0.05.
The research study was performed in accordance with the Declaration of Helsinki. The study was approved by
the local IRB and the requirement for informed consent was waived because of the retrospective nature of this
study.

Results

Clinicopathological features of left and right sided breast cancer. In the SEER database, 881,320
patients were included in this analysis. Left sided and right sided tumors were seen in 50.8% and 49.2% of
patients respectively. The baseline demographic and clinical characteristics based on laterality are summarized
in Table 1. Poorly differentiated and undifferentiated tumors, as well as hormone negative and HER2 positive
tumors were significantly more prominent on the left side compared to the right side (p < 0.001). In the TCGA
cohort, left sided and right sided tumors were seen in 52.0% and 48.0% of patients respectively. A higher number
of grade 2 and 3 tumors was seen on the left side compared to the right (p = 0.02). No other statistically significant differences in clinical features were seen in that cohort (Table 2). Lastly, in our institutional cohort of 155
patients, left sided and right sided tumors were seen in 50.3% and 49.7% of patients respectively. No statistically
significant differences were seen in clinicopathological characteristics (Supplemental Table S1).
Survival outcomes of left and right sided breast cancer. In the SEER population, left sided breast
cancer demonstrated poorer OS and CSS compared to right sided breast cancer (left vs right HR 1.02, p < 0.001,
Table 3). Left sided tumors continued to show poorer outcomes even after adjusting for grade, stage, and hormone receptor status (left vs right HR 1.05, 95% CI 1.01,1.08; p = 0.011; Table 4). The results of the interaction
analysis showed no significant interaction between laterality and age, grade, stage, receptor status or number
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Left

Right

Overall

447,401 (50.8%)

433,919 (49.2%)

881,320 (100%)

P-value

Overall
N (%)
Age
< 45

59,138 (13.2%)

58,582 (13.5%)

117,720 (13.4%)

45–65

214,751 (48.0%)

209,059 (48.2%)

423,810 (48.1%)

65 +

173,512 (38.8%)

166,278 (38.3%)

339,790 (38.6%)

< 0.001

Grade
Well diff

84,957 (21.0%)

84,542 (21.5%)

169,499 (21.2%)

Moderately diff

172,823 (42.6%)

168,392 (42.8%)

341,215 (42.7%)

Poorly diff

141,671 (35.0%)

135,057 (34.3%)

276,728 (34.6%)

Undifferentiated

5,880 (1.5%)

5,580 (1.4%)

11,460 (1.4%)

< 0.001

AJCC stage
I

221,671 (49.5%)

215,580 (49.7%)

437,251 (49.6%)

II

163,139 (36.5%)

157,805 (36.4%)

320,944 (36.4%)

III

62,591 (14.0%)

60,534 (14.0%)

123,125 (14.0%)

0.444

ER
Negative

82,598 (20.6%)

77,862 (20.0%)

160,460 (20.3%)

Positive

318,300 (79.4%)

311,694 (80.0%)

629,994 (79.7%)

< 0.001

PR
Negative

124,578 (31.5%)

117,880 (30.7%)

242,458 (31.1%)

Positive

271,391 (68.5%)

266,691 (69.3%)

538,082 (68.9%)

< 0.001

HER2
Negative

117,577 (85.1%)

114,648 (85.4%)

232,225 (85.2%)

Positive

20,597 (14.9%)

19,645 (14.6%)

40,242 (14.8%)

0.041

Hormone receptor
Triple negative

15,818 (11.5%)

14,976 (11.2%)

30,794 (11.3%)

Triple positive

10,195 (7.4%)

9,796 (7.3%)

19,991 (7.4%)

ER + /PR + /HER2-

88,385 (64.2%)

87,035 (65.0%)

175,420 (64.6%)

ER-/PR-/HER2 +

6,199 (4.5%)

5,841 (4.4%)

12,040 (4.4%)

ER or PR +

17,065 (12.4%)

16,184 (12.1%)

33,249 (12.2%)

< 0.001

Nodes positive
0

273,666 (67.1%)

265,830 (67.1%)

539,496 (67.1%)

1–3

90,701 (22.2%)

87,494 (22.1%)

178,195 (22.2%)

4–9

29,646 (7.3%)

28,218 (7.1%)

57,864 (7.2%)

10 +

13,984 (3.4%)

14,360 (3.6%)

28,344 (3.5%)

< 0.001

Table 1.  The Surveillance, Epidemiology, and End Results (SEER) program: baseline characteristics based on
laterality. ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2,
AJCC American Joint Committee on Cancer, Min minimum, Max maximum.

of positive nodes (Fig. 1). Although tumors that are ER and/or PR negative appear to have worse outcomes on
the left side (HR 1.03, p < 0.001). No significant differences in survival were noted in the TCGA or institutional
cohorts (data not shown).

Transcriptome profiles and biological characteristics of left and right sided breast cancer. GSEA demonstrated that cell proliferation and cell-cycle related gene sets including G2M checkpoint,

Mitotic spindle, E2F targets and MYC targets, were significantly enriched in left sided tumors (Fig. 2). Furthermore, out of the 865 genes that were significantly highly expressed on the left side, we identified specific genes
that are associated with breast tumorigenesis: including BRCA1, BRCA2, BRIP1, CHEK2, FANCC, PALB2,
TP53 and MSH6. No statistically significant differences were observed in mutation count and CYT between the
sides (Supplemental Fig. S1).

Pathological complete response in left and right sided breast cancer. In our institutional cohort
of 155 patients that underwent neoadjuvant chemotherapy, there was a lower rate of pathologic complete
response (pCR) in response to neoadjuvant chemotherapy with left sided tumors as compared to right sided
tumors (15.4% versus 29.9% respectively, p = 0.036) (Fig. 3). This held true when adjusted for grade, stage, and
receptor status (OR 0.43 (0.18–0.99), p = 0.048).
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Variable

Left

Right

P-value

552 (52%)

510 (48%)

Overall
N (%)
Grade
1

28 (5.0%)

48 (9.2%)

2

144 (25.7%)

122 (23.5%)

3

121 (21.6%)

105 (20.2%)

0.021

Stage
I

92 (16.4%)

90 (17.3%)

II

324 (57.8%)

287 (55.2%)

III

125 (22.3%)

121 (23.3%)

0.76

Tumor size
T1

139 (24.8%)

139 (26.7%)

T2

324 (57.8%)

292 (56.2%)

T3

67 (11.9%)

66 (12.7%)

T4

21 (3.7%)

12 (2.3%)

0.485

Nodal involvement
Negative

255 (45.5%)

225 (43.3%)

Positive

296 (52.8%)

284 (54.6%)

0.537

Subtype
ER+/PR+/HER2−

205 (36.5%)

182 (35.0%)

ER+/PR+/HER2+

65 (11.6%)

53 (10.2%)

ER−/PR−/HER2+

23 (4.1%)

16 (3.1%)

Triple negative

56 (10.0%)

56 (10.8%)

0.766

ER status
Negative

125 (22.3%)

107 (20.6%)

Positive

400 (71.3%)

379 (72.9%)

0.502

PR status
Negative

175 (31.2%)

155 (29.8%)

Positive

346 (61.7%)

331 (63.7%)

0.591

Her2 status
Negative

287 (51.2%)

260 (50.0%)

Positive

88 (15.7%)

70 (13.5%)

0.53

Table 2.  The Cancer Genome Atlas (TCGA): baseline characteristics based on laterality. ER estrogen receptor,
PR progesterone receptor, Her-2 human epidermal growth factor receptor 2.

Overall survival

Cancer specific survival

5 yr rate (95%
CI)

10 yr rate (95%
CI)

Hazard ratio
(95% CI)

P-value

5 yr rate (95%
CI)

10 yr rate (95% Hazard ratio
CI)
(95% CI)

Total

84.7 (84.6, 84.8)

70.6 (70.5, 70.7)

–

< 0.001

91.4 (91.4, 91.5) 85.4 (85.3, 85.5) –

Left

84.5 (84.4, 84.6)

70.4 (70.3, 70.6)

1.02 (1.01, 1.03)

91.3 (91.2, 91.4) 85.3 (85.1, 85.4) 1.02 (0.01, 1.04)

Right

84.9 (84.8, 85.0)

70.8 (70.6, 71.0)

1.00

91.6 (91.5, 91.7) 85.6 (85.5, 85.7) 1.00

P-value
< 0.001

Table 3.  Overall survival and cancer-specific survival rates in left and right breast cancer. Yr year, CI
confidence interval.

Discussion

The most recently published comprehensive analysis of breast cancer laterality in a large population cohort
(SEER), analyzed patients between 1973 and 201011. Our updated SEER analysis confirms the persistence of left
breast cancer predominance; with a slightly higher prevalence of ER/PR negative and HER-2 positive tumors on
the left. The significant differences seen in clinicopathological variables by laterality appear to have no clinical
relevance and are largely driven by the large sample sizes. However, we do interestingly note a slight survival
disadvantage to left sided breast cancer compared to right side with a hazard ratio of 1.05. In another SEER analysis, Bao et al. showed slightly worse breast cancer specific mortality in the left central portion of the breast (HR,
1.100; P = 0.013, using the right side as the reference), with no other significant interactions between laterality and
primary tumor site seen in their s tudy28. Our study did not include specific information on primary tumor site
within each breast, therefore, we are not able to make definitive conclusions regarding the relationship between
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Variable

Hazard ratio

P-value

Laterality
Left vs right

1.05 (1.01, 1.08)

0.011

45–65 vs < 45

1.05 (0.99, 1.12)

< 0.001

65 + vs < 45

2.92 (2.74, 3.10)

Age

Grade
Moderately diff. vs well diff

1.12 (1.05, 1.18)

Poorly diff. vs well diff

1.68 (1.59, 1.79)

Undifferentiated vs well diff

1.98 (1.59, 2.48)

< 0.001

AJCC stage
II vs I

1.71 (1.62, 1.80)

III vs I

3.80 (3.52, 4.10)

< 0.001

Nodes positive
1–3 vs 0

1.28 (1.22, 1.34)

4–9 vs 0

1.30 (1.20, 1.41)

10 + vs 0

2.08 (1.91, 2.26)

< 0.001

Hormone receptor
Triple positive vs Triple negative

0.37 (0.34, 0.40)

ER+/PR+/HER2− vs triple negative

0.40 (0.38, 0.42)

ER−/PR−/HER2+ vs Triple negative

0.54 (0.50, 0.58)

ER/PR+ vs triple negative

0.64 (0.60, 0.67)

< 0.001

Table 4.  Multivariate survival analysis while adjusting for grade, stage and tumor subtype. Yr year, CI
confidence interval, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor
receptor 2, AJCC American Joint Committee on Cancer.

laterality and the tumor location within each breast. Most other previous studies showed no difference in survival
outcomes by breast cancer laterality2,3,5,10,29, although, there was a single study of 5,459 breast cancer patients
in Egypt which showed significantly worse survival in left sided breast cancer compared to r ight30. That being
said, patients with left sided breast cancer treated with radiation therapy were at greater risk of cardiovascular
complications, and historically had worse o
 utcomes31,32.
While many studies discussed possible causes for left sided predominance in breast c ancer7–9,12,33,34, no previous research have looked at underlying genomic differences between left and right sided breast cancer. We
noted no differences in tumor infiltrating immune cells by laterality, however, several cell proliferation gene sets
were found to be significantly enriched on the left side, indicating distinct underlying biologic characteristics
between the two sides. This observation was further illustrated in our institutional analysis of the neoadjuvant
cohort, where left sided tumors were less likely to achieve a pCR compared to right sided tumors. Even though
prior research considered higher proliferation rates to be a predictor of pCR35, left sided tumors had lower rates
of pCR in our institutional cohort, despite having more prominent cell proliferation gene sets on that side. These
findings suggest the presence of a complex interplay between the biology of left sided tumors and response to
treatment, regardless of other clinical characteristics. Additionally, more comprehensive approaches, such as
investigating the role of the tumor microenvironment and comparing differences in immune cells by breast
cancer laterality, may provide further insight to this hypothesis. Even among the cancer cells, it may be interesting to investigate the differences in intertumoral heterogeneity by laterality. In conclusion, we cannot help but
speculate whether left sided breast cancer is more prominent than right sided breast cancer due to an underlying
biological process that was not previously discussed in literature, and whether this distinct process makes left
sided breast cancer more chemo-resistant than right sided cancer given the noted lower pCR rates. That being
said, the close similarity in survival outcomes between both sides may stir us away from taking a more aggressive
management approach with left sided tumors.
This study has certain limitations. Being a retrospective analysis, we are unable to determine definitive causation to the excess number of tumors found in the left breast but could only show association. Furthermore,
possible confounding variables could not be identified retrospectively, due to lack of awareness regarding how
they interact with our outcomes and results, although multivariate analysis was used to control for confounding
variables. Another limitation is the large number of missing HER2-expression data in our cohort. Therefore, one
can argue that receptor status can be a surrogate for the gene expression subtype classification reported by Perou
et al.36 in only a minority of the cohort. Although, many clinicians make clinical decisions using the receptor
status, and not the surrogate of the molecular subtype. To this end, we believe our results on receptor status are
informative to such clinicians. Despite these limitations, our study provides novel data on breast cancer laterality
and adds a unique perspective to underlying biology of left sided breast cancer.
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Figure 1.  The Surveillance, Epidemiology, and End Results (SEER) program: interaction analysis. ER estrogen
receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, AJCC American Joint
Committee on Cancer, Diff differentiated.

Conclusions

In conclusion, we observe that left sided breast tumors have a more proliferative genomic profile, lower responses
to neoadjuvant chemotherapy, and slightly worse long-term outcomes compared to right sided breast cancer.
These findings are quite novel and if validated, may enhance our management approaches in the future.
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Figure 2.  Proliferation related gene sets enriched in Left breast cancer.

Figure 3.  Pathological Complete Response (pCR) in left and right sided breast cancer.
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Data availability

The datasets used and/or analyzed during the current study are available from the corresponding author on
reasonable request.
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